Lupin has announced that the United States Food and Drug Administration's inspection of its Nagpur facility has come to a close. In an exchange filing published on November 15, the pharma company said that the drug regulator concluded the inspection of its Nagpur Unit-1 Facility with "No Observations”.
Lupin announces closure of US FDA insepction of Nagpur facility with zero observations